Cepheid Executive and Leadership Team

Charles Mwangi, the Senior Vice President & Chief Financial Officer at Cepheid, manages the company's financial strategy and operations. Overseeing all fiscal activities, Mwangi ensures robust financial health and supports Cepheid's growth objectives. This role involves strategic financial planning, resource allocation, and risk management to sustain the development and manufacturing of advanced molecular diagnostic systems. By guiding financial decisions, Charles Mwangi directly contributes to the company's ability to deliver sophisticated genetic testing solutions to institutions worldwide. The financial acumen provided by Mwangi underpins Cepheid's market position and its capacity to innovate in the molecular diagnostics sector, ensuring long-term stability and operational excellence.

Pawan Varshney, the Interim Chief Financial Officer at Cepheid, provides critical financial oversight during a transitional period. Managing day-to-day financial operations, Varshney ensures continuity and stability for the company's fiscal functions. This leadership role involves supporting the ongoing development and manufacturing of Cepheid's molecular diagnostic systems and tests. By maintaining sound financial practices, Pawan Varshney aids in the company's mission to automate complex genetic testing procedures. The interim financial guidance from Varshney is essential for sustaining Cepheid's operational capacity and its commitment to delivering advanced genetic-based disease detection solutions to a global market.

James Green, the Chief Technology Officer & Vice President, R&D at Cepheid, directs the company's technological vision and research and development initiatives. Overseeing the innovation pipeline, Green ensures Cepheid's molecular systems and tests remain at the forefront of diagnostic technology. This leadership involves guiding the development of automated solutions that simplify complex manual procedures for genetic testing. By fostering a culture of scientific inquiry, Green's team delivers advanced genetic-based disease detection capabilities. The strategic direction provided by James Green supports the company's mission to empower institutions with sophisticated genetic testing tools, driving advancements in molecular diagnostics and enhancing global health outcomes.

Connie Price, the Chief Medical Officer at Cepheid, directs the company's medical and scientific strategy, ensuring clinical relevance and efficacy of its molecular diagnostic solutions. Overseeing the clinical application of Cepheid's technologies, Price guides the development of tests that automate complex genetic analyses for organisms and diseases. This leadership ensures that the company's systems meet the rigorous demands of healthcare institutions seeking sophisticated genetic testing. By providing medical expertise, Connie Price champions the advancement of diagnostic capabilities, supporting the company's mission to deliver accurate and efficient testing. The strategic medical insights from Price are vital for Cepheid's continued innovation and impact on global health.

David Persing, the Executive VP, Chief Medical & Scientific Officer at Cepheid, spearheads the company's overarching medical and scientific direction. Guiding the integration of cutting-edge research with product development, Persing ensures Cepheid's molecular systems and tests offer unparalleled sophistication in genetic analysis. This role involves driving innovation in automated genetic testing, simplifying complex manual procedures for institutions of all sizes. By championing scientific rigor, David Persing enhances the company's ability to detect organisms and genetic-based diseases effectively. The profound scientific leadership provided by Persing is fundamental to Cepheid's mission of advancing molecular diagnostics and improving patient outcomes worldwide.